Lesson
Block Isoleucine Loading at a Selective Bacterial Target
Mupirocin is a pseudomonic acid antibacterial that binds bacterial isoleucyl transfer RNA synthetase. Preventing isoleucine from being attached to transfer RNA interrupts bacterial protein synthesis without using the human cytosolic enzyme as its principal target.
- Pseudomonic acid
- Isoleucyl tRNA synthetase
- Protein synthesis
- Selective target
- Concentration effect
The scaffold resembles the enzyme reaction intermediate.
Mupirocin occupies bacterial isoleucyl transfer RNA synthetase.
Isoleucine cannot be loaded for translation.
Growth is inhibited and high local exposure can kill susceptible bacteria.
Identify the target precisely
Mupirocin inhibits bacterial isoleucyl transfer RNA synthetase. It does not act at the 30S or 50S ribosomal subunit and does not inhibit peptidoglycan cross linking.
Connect structure to selectivity
Its pseudomonic acid scaffold resembles features of the isoleucyl adenylate reaction intermediate. Strong bacterial enzyme binding and much weaker interaction with the corresponding human enzyme support local selectivity.
Use concentration language carefully
At lower concentrations mupirocin is generally bacteriostatic, while concentrations achieved by topical use can be bactericidal against susceptible organisms. Local concentration does not establish systemic treatment.
Keep resistance inside the mechanism
A changed native isoleucyl transfer RNA synthetase can reduce binding. An acquired alternate enzyme can create high level resistance and defeat the local concentration advantage.
Quick check
Lesson
Treat the Formulation as Part of the Drug
Mupirocin products share the active moiety but differ by salt, vehicle, route, approved use, and availability. A dermal ointment that contains polyethylene glycol is not automatically interchangeable with the discontinued paraffin based nasal product.
- Dermal ointment
- Dermal cream
- Nasal ointment
- Polyethylene glycol
- Paraffin vehicle
Current dermal product treats susceptible impetigo.
A separate formulation treats selected traumatic skin infection.
The dedicated single use product was discontinued.
Do not infer route interchangeability from 2% strength.
Separate the dermal products
Current mupirocin ointment contains 2% mupirocin in polyethylene glycol 400 and 3350 and is labeled for topical impetigo. Mupirocin calcium cream is a separate oil and water emulsion used for susceptible secondarily infected traumatic skin lesions.
Reconstruct the nasal product
The dedicated product contained mupirocin calcium equivalent to 2% mupirocin in a paraffin and glycerin ester base. It was packaged as a single use 1 gram tube for intranasal administration.
Name current availability
The sponsor discontinued Bactroban Nasal in 2018 and FDA withdrew its application in 2025 at the sponsor's request. FDA determined that withdrawal was not due to safety or effectiveness, allowing a future generic application to rely on it.
Do not improvise substitution
Current dermal ointment labeling states that it is not formulated for mucosal surfaces. When an institutional decolonization protocol uses available mupirocin intranasally, verify the exact product, evidence, policy, and patient instructions rather than assuming every tube is approved for the nose.
Quick check
Lesson
Use Dermal Mupirocin for a Defined Local Infection
Current mupirocin ointment labeling covers topical treatment of impetigo caused by susceptible Staphylococcus aureus or Streptococcus pyogenes. Local therapy still requires syndrome confirmation, lesion assessment, technique, response monitoring, and escalation when disease is extensive or invasive.
- Impetigo
- S. aureus
- S. pyogenes
- Three times daily
- Response checkpoint
Identify a superficial bacterial process.
Use a small amount for up to 10 days.
Lack of improvement triggers reassessment.
Source control or systemic therapy may be needed.
Start with the labeled syndrome
Apply a small amount of current mupirocin ointment to the affected skin three times daily for up to 10 days. A clean gauze dressing may cover the area when appropriate.
Keep the organism claim narrow
Clinical evidence supports susceptible S. aureus and S. pyogenes in impetigo. Additional in vitro activity does not prove effectiveness for every organism, wound, abscess, or invasive infection.
Escalate beyond local therapy
Extensive disease, systemic signs, rapidly progressive inflammation, deep infection, abscess, poor perfusion, immune compromise, or treatment failure can require culture, drainage, systemic therapy, or another diagnosis.
Set an early checkpoint
The current ointment label instructs patients to contact a clinician when impetigo has not improved within 3 to 5 days. Reassessment is better than continuing an ineffective local course indefinitely.
Quick check
Lesson
Distinguish Carriage from Active Infection
Nasal colonization means S. aureus is present without causing local disease. Colonization can contribute to transmission and later infection, but eradication of carriage is not treatment for bacteremia, pneumonia, cellulitis, abscess, or another active infection.
- Colonization
- Infection
- Anterior nares
- Reservoir
- Transmission
A screen identifies organisms without proving infection.
Nares can seed hands, skin, devices, and wounds.
Decolonization reduces carriage for a defined purpose.
Clearance can be temporary.
Define the state
A positive nasal screen can identify carriage in a person without nasal symptoms. It does not establish an invasive infection and should not be assigned an infection syndrome by itself.
Understand the reservoir
The anterior nares are a common S. aureus reservoir. Carriage can seed hands, skin, devices, wounds, environmental surfaces, or the patient's own later infection.
Match the intervention to the goal
Decolonization attempts to reduce or eradicate carriage for a defined prevention purpose. Antibiotic treatment addresses an active infection at a clinically involved site, often with systemic exposure and source control.
Expect the state to change
A successful course does not guarantee permanent clearance. Recolonization can follow incomplete adherence, untreated body sites, household or healthcare exposure, or resistant organisms.
Quick check
Lesson
Make the Five Day Nasal Course Executable
The former dedicated nasal label used one single use tube twice daily for five days. Half of the dispensed ointment went into each nostril, followed by repeated compression and massage of the nose to distribute the product.
- Half tube per nostril
- Twice daily
- Five days
- One minute massage
- Discard tube
Place the designated amount in each nostril.
Press and release repeatedly.
Distribute ointment through the anterior nares.
Prevent eye exposure, sharing, and tube reuse.
Measure by package design
The historical 1 gram single use tube delivered about 0.5 gram total, or about 0.25 gram per nostril. The unused contents were not saved for a later dose.
Distribute the ointment
After placing approximately half in each nostril, press the sides of the nose together and release repeatedly while gently massaging for about one minute. This spreads the product through the anterior nares.
Protect technique and hygiene
Wash hands before and after administration, avoid eye contact, do not share a tube, discard it after use, and follow the current institutional directions for the actual product supplied.
Avoid unstudied combinations
The dedicated label advised against concurrent intranasal products because combined application had not been studied. Medication reconciliation should include sprays, gels, rinses, and antiseptics used in the nose.
Quick check
Lesson
Place Mupirocin Inside the Current Prevention Strategy
Current CDC guidance uses intranasal mupirocin with chlorhexidine for selected high risk patients and periods. SHEA, IDSA, and APIC guidance supports protocol based universal or targeted strategies according to the care setting and prevention goal.
- ICU strategy
- Central access
- High risk surgery
- Targeted decolonization
- Universal decolonization
Nasal treatment and daily chlorhexidine address high risk admission.
Central access outside ICU can justify a supplemental protocol.
High risk procedures use nasal and skin measures.
Screening and decolonization follow the infection control plan.
Use the ICU core strategy
CDC recommends reducing S. aureus carriage in all ICU patients with intranasal mupirocin twice daily for five days plus daily chlorhexidine bathing for the duration of the ICU stay. Iodophor can be considered as an alternative nasal agent.
Recognize the device pathway
For non ICU inpatients with a central venous catheter or midline, CDC lists chlorhexidine plus nasal decolonization as a supplemental strategy. The benefit is linked to a high risk device period, not a universal outpatient rule.
Prepare for high risk surgery
CDC recommends an intranasal antistaphylococcal agent and chlorhexidine before cardiothoracic, orthopedic, and neurosurgical procedures. A five day mupirocin course is one possible nasal regimen.
Choose targeted or universal deliberately
Targeted decolonization uses screening to identify carriers. Universal decolonization treats the defined at risk population without waiting for a screen. Institutional epidemiology, logistics, adherence, resistance, and protocol design shape the choice.
Quick check
Lesson
Treat Decolonization as a Bundle, Not a Tube
Nasal therapy addresses one reservoir. Chlorhexidine, hand hygiene, contact precautions when indicated, device care, environmental cleaning, staff competency, adherence, and outcome surveillance address the wider transmission system.
- Chlorhexidine
- Hand hygiene
- Device care
- Environmental cleaning
- Adherence
Reduce the nasal S. aureus reservoir.
Reduce organism burden beyond the nares.
Interrupt transfer and protect access sites.
Measure adherence, resistance, and outcomes.
Learn from universal ICU evidence
The REDUCE MRSA trial found that universal chlorhexidine bathing plus nasal mupirocin reduced MRSA clinical isolates by 37% and all cause bloodstream infections by 44% compared with screening and isolation alone.
Do not assign the full effect to one product
The trial tested a combined strategy. It cannot establish how much of the outcome came from mupirocin alone, chlorhexidine alone, or their interaction.
Build implementation reliability
Standardized order sets, adequate supplies, competency based training, clear ownership, and observed technique can matter as much as the written regimen. Missed applications and incomplete skin antisepsis weaken the bundle.
Measure the system
Track protocol adherence, MRSA cultures, healthcare associated infections, device events, local susceptibility, adverse effects, and recolonization. A decolonization program needs feedback rather than automatic continuation.
Quick check
Lesson
Protect a Narrow Local Tool from Unnecessary Exposure
Mupirocin resistance can follow target mutation or acquisition of an alternate isoleucyl transfer RNA synthetase. Repeated or broad use creates selection pressure, and routine susceptibility testing may not be available in every laboratory.
- Low level resistance
- High level resistance
- mupA
- Selection pressure
- Stewardship
Point mutations can produce low level resistance.
An alternate enzyme can create high level resistance.
Unnecessary courses increase pressure.
Check adherence, sites, recolonization, and susceptibility.
Separate the resistance levels
Low level resistance usually reflects point mutations in the native target. High level resistance is often associated with transferable mupA or mupB genes that encode an alternate enzyme.
Connect resistance to failure
A resistant organism may persist despite apparently correct technique. Failure can also reflect missed doses, untreated body sites, recolonization, product misuse, or a prevention goal that was never achievable with nasal therapy alone.
Use population exposure carefully
Universal strategies can be appropriate in defined high risk settings, but indiscriminate or chronic community use has no equivalent evidence base and can increase antibacterial pressure.
Respond with investigation
Persistent carriage should prompt verification of the product and course, adherence, sampling timing, other colonized sites, local epidemiology, and susceptibility options. Repeating the same regimen without explanation is not stewardship.
Quick check
Lesson
Keep Local Therapy Local and Still Screen for Risk
Systemic absorption through intact skin is minimal, but formulation, damaged skin, mucosa, age, hypersensitivity, renal function, pregnancy, lactation, and treatment area change the safety assessment.
- Local irritation
- Hypersensitivity
- Polyethylene glycol
- Pregnancy
- Lactation
Burning, drying, itching, or rash can limit use.
Anaphylaxis, angioedema, or generalized rash needs urgent action.
Large damaged surfaces and renal impairment increase concern.
Wash treated breast tissue before feeding.
Recognize local and allergic reactions
Burning, stinging, itching, rash, dryness, rhinitis, headache, and pharyngitis can occur depending on formulation and route. Anaphylaxis, urticaria, angioedema, and generalized rash require immediate discontinuation and evaluation.
Assess the polyethylene glycol vehicle
Dermal ointment should not be used where large quantities of polyethylene glycol could be absorbed from open wounds or damaged skin, especially with moderate or severe renal impairment. This warning belongs to that formulation and exposure scenario.
Use current pregnancy language
Current topical labeling reports insufficient human data to define drug associated pregnancy risk. Absorption through intact skin is minimal, and animal organogenesis studies did not show developmental toxicity at the studied exposures.
Protect the breastfed child
Topical exposure is not expected to produce meaningful infant exposure through milk because maternal absorption is minimal. If a breast or nipple is treated, wash it thoroughly before feeding to reduce direct oral exposure.
Quick check
Lesson
Close the Loop from Indication to Outcome
A safe mupirocin plan verifies what is being treated, why decolonization is indicated, which product and route are being used, how the application will be performed, what belongs in the prevention bundle, and what happens when the expected result is not achieved.
- Indication
- Exact product
- Technique
- Response
- Escalation
Treatment and decolonization are different goals.
Route and vehicle must match the plan.
Ask for demonstration when administration matters.
Reassess infection, resistance, adherence, and protocol.
Start with purpose
State whether the goal is dermal infection treatment, targeted carriage eradication, universal suppression during a high risk period, preoperative prevention, or outbreak control. The same tube does not make these purposes equivalent.
Teach observable technique
Ask the patient or clinician to demonstrate application amount, placement, massage when nasal use is protocol directed, hand hygiene, dressing use, eye protection, and safe disposal.
Define success before treatment
For impetigo, improvement should begin within several days. For a decolonization program, the outcome may be protocol completion, reduced clinical infection, or a follow up culture at a specified time, depending on policy.
Escalate the right problem
New fever, spreading erythema, abscess, systemic illness, severe allergy, persistent local irritation, or failed decolonization needs reassessment. Do not use topical therapy to delay source control or systemic treatment.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 172 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.